No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
525 |
4. Check minimum number of eventsNone |
525 |
5. Include endpointsNone |
525 |
6. Filter based on genotype QC (FinnGen only) |
525 |
Control definitions (FinnGen only)
- Control exclude
- L12_URTICARIAERYTHEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Universal erythroderma, KELA reimbursement
based on the number of shared cases.
Similar with more cases:
- Atopic dermatitis, strict definition with reimbursement
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any reimbursement code in KELA
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3118 | 1019 | 2077 |
| Only index persons | 2650 | 908 | 1742 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.06 |
| Only index persons | 0.06 | 0.03 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 50.11 | 51.31 | 49.42 |
| Only index persons | 48.21 | 49.83 | 47.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 525 | 188 | 337 |
| Unadjusted period prevalence (%) | 0.12 | 0.06 | 0.15 |
| Median age at first event (years) | 47.64 | 47.40 | 47.77 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 490
- Matched controls
- 4898
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05BB02
ATC
acitretin; oral
260.7
323.0
326
37
134
Kela drug reimbursment
General erythroderma
+∞
323.0
490
*
L40.0
ICD-10 Finland
Psoriasis vulgaris
98.0
286.2
307
82
D05AX02
ATC
calcipotriol; topical
68.5
231.2
264
82
D05AX52
ATC
calcipotriol, combinations; topical
52.5
210.7
255
99
E000001
ATC
NA
25.1
208.2
373
552
E0000UV
ATC
NA
39.6
204.1
455
1209
D07AC01
ATC
betamethasone; topical
27.8
197.9
431
1019
D07XC01
ATC
betamethasone, combinations; topical
25.8
196.8
312
311
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
26.0
176.9
268
217
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
406.2
150.7
144
5
E000002
ATC
NA
18.7
142.7
243
244
D07AD01
ATC
clobetasol; topical
14.3
134.1
269
385
E000003
ATC
NA
31.4
131.5
179
88
D07AB02
ATC
hydrocortisone butyrate; topical
11.0
125.2
329
768
D07AB08
ATC
desonide; topical
15.2
118.3
218
245
D05AX03
ATC
calcitriol; topical
83.7
118.1
130
21
D07AC13
ATC
mometasone; topical
9.9
116.5
332
854
L40.5
ICD-10 Finland
Arthropathic psoriasis
65.7
101.4
116
23
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
42.8
90.9
113
34
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
64.8
89.8
103
20
L04AD01
ATC
ciclosporin; systemic
53.6
89.4
106
25
L26
ICD-10 Finland
Exfoliative dermatitis
979.4
86.3
82
*
L40.8
ICD-10 Finland
Other psoriasis
173.2
84.0
86
6
D07AA02
ATC
hydrocortisone; topical
9.0
78.9
192
327
TQW80
NOMESCO Finland
Local dermatologic skincare
25.2
76.2
109
55
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
58.5
74.5
87
18
D02AE01
ATC
carbamide; topical
13.2
73.8
138
141
E000006
ATC
NA
13.4
73.8
137
138
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
140.2
68.9
72
6
L20.0
ICD-10 Finland
Besnier prurigo
14.0
67.2
121
112
L40.9
ICD-10 Finland
Psoriasis, unspecified
48.2
67.0
81
20
L04AA01
ATC
[U] ciclosporin; systemic
48.2
67.0
81
20
E000007
ATC
NA
14.1
64.9
116
105
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
9.2
64.8
149
221
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
110.6
62.6
67
7
D02AX
ATC
Other emollients and protectives
19.5
60.5
94
59
L40
ICD-10 Finland
Psoriasis
34.1
59.8
78
27
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
15.8
58.7
99
77
L04AC05
ATC
ustekinumab; parenteral
133.7
56.2
59
5
D11AH01
ATC
tacrolimus; topical
61.1
55.3
64
12
L04AB04
ATC
adalimumab; parenteral
24.0
51.5
74
36
D07BA04
ATC
hydrocortisone and antiseptics; topical
7.3
50.7
135
242
N05BB01
ATC
hydroxyzine; systemic
9.4
49.0
108
143
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
4.8
48.8
209
662
L04AC10
ATC
secukinumab; parenteral
113.5
47.8
51
5
D05AA
ATC
Tars
132.6
45.6
48
*
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
6.2
45.4
138
292
M07.3
ICD-10 Finland
Other psoriatic arthropathies
40.4
40.9
51
14
D11AX14
ATC
[U] tacrolimus; topical
57.2
36.0
42
8
H02AB06
ATC
prednisolone; systemic
3.4
35.5
297
1540
D11AH02
ATC
pimecrolimus; topical
94.1
32.2
35
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.7
30.3
94
196
D09AB01
ATC
zinc bandage without supplements; topical
13.1
29.7
53
45
L04AB01
ATC
etanercept; parenteral
21.3
29.3
43
22
L04AC13
ATC
ixekizumab; parenteral
159.3
29.0
30
*
S91
ICPC
Psoriasis
41.7
28.4
35
9
L04AC16
ATC
guselkumab; systemic
285.8
27.0
27
*
L40.4
ICD-10 Finland
Guttate psoriasis
63.7
26.3
30
5
R06AE07
ATC
cetirizine; oral
2.8
26.1
247
1289
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.3
24.9
103
288
E000004
ATC
NA
13.4
24.1
42
34
D07AC14
ATC
methylprednisolone aceponate; topical
7.2
24.0
60
93
395
Kela drug reimbursment
Dupilumab
240.7
22.8
23
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
54.7
22.3
26
5
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
84.0
21.9
24
*
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
120.4
21.8
23
*
XQ800
NOMESCO Finland
Prick test
5.7
21.4
64
126
D05AC01
ATC
dithranol; topical
80.4
20.9
23
*
D07CC01
ATC
betamethasone and antibiotics; topical
3.5
20.7
108
366
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
208.0
19.7
20
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.3
19.3
76
201
R06AE09
ATC
levocetirizine; oral
3.5
18.8
98
329
XQ848
NOMESCO Finland
Dermatological photography
7.7
18.8
44
62
C84.0
ICD-10 Finland
Mycosis fungoides
197.2
18.7
19
*
D11AH05
ATC
dupilumab; topical
197.2
18.7
19
*
XQ802
NOMESCO Finland
Epicutan test
7.8
18.5
43
60
D07BC01
ATC
betamethasone and antiseptics; topical
3.5
17.9
91
300
L04AA32
ATC
apremilast; oral
98.6
17.7
19
*
L04AA11
ATC
[U] etanercept; parenteral
98.6
17.7
19
*
D05AX
ATC
Other antipsoriatics for topical use
175.7
16.6
17
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
16.0
242
1489
D05AX05
ATC
tazarotene; topical
62.1
15.9
18
*
69600
ICD-8 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
165.0
15.6
16
*
L40.1
ICD-10 Finland
Generalized pustular psoriasis
165.0
15.6
16
*
D11AX15
ATC
[U] pimecrolimus; topical
39.4
15.5
19
5
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.6
15.5
55
131
L04AC18
ATC
risankizumab; parenteral
+∞
14.7
14
*
D07XB05
ATC
dexamethasone, combinations; topical
7.1
14.0
34
51
D07XB01
ATC
flumetasone, combinations; topical
18.2
13.9
21
12
WQ031
NOMESCO Finland
NA
143.8
13.5
14
*
L30.3
ICD-10 Finland
Infective dermatitis
5.2
13.5
42
87
J01DA09
ATC
[U] cefadroxil; inhalant, oral
2.3
13.1
157
848
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
71.7
12.6
14
*
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
71.7
12.6
14
*
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
20.7
12.5
18
9
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.6
12.5
98
426
R06AX27
ATC
desloratadine; oral
2.3
12.4
139
726
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
8.3
12.0
26
33
TQW99
NOMESCO Finland
Other minor procedure on skin
4.1
11.9
47
124
L20
ICD-10 Finland
Atopic dermatitis
7.8
11.6
26
35
J01DA01
ATC
[U] cefalexin; systemic
2.0
11.3
312
2316
J01FF01
ATC
clindamycin; systemic
2.1
11.1
148
828
H02AB07
ATC
prednisone; oral
2.6
11.0
86
370
H02AB09
ATC
hydrocortisone; systemic
8.1
11.0
24
31
S01GX01
ATC
cromoglicic acid; ophthalmic
2.4
10.8
102
486
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
5.9
10.6
29
52
N06AA12
ATC
doxepin; systemic
4.2
10.6
40
102
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
10.4
10
*
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
6.0
10.4
28
49
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
5.8
10.1
28
51
A07EC01
ATC
sulfasalazine; oral, rectal
3.1
9.9
56
197
RJ420
NOMESCO Finland
NA
26.6
9.9
13
5
D11AH04
ATC
alitretinoin; oral
101.9
9.4
10
*
A46
ICD-10 Finland
Erysipelas
2.4
9.4
84
387
L27.2
ICD-10 Finland
Dermatitis due to ingested food
37.4
9.0
11
*
SPAT1262
SPAT
Handing over of treatment supplies
2.1
9.0
109
579
L04AX01
ATC
azathioprine; systemic
3.7
9.0
38
108
RS340
NOMESCO Finland
NA
24.5
8.9
12
5
ZX112
NOMESCO Finland
Subcutaneous
6.8
8.7
21
32
RJ411
NOMESCO Finland
NA
16.6
8.6
13
8
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
91.5
8.4
9
*
J01DB01
ATC
cefalexin; oral
1.9
8.4
395
3335
WXQ24
NOMESCO Finland
UVB/UVA light therapy
+∞
8.4
8
*
Q80.8
ICD-10 Finland
Other congenital ichthyosis
+∞
8.4
8
*
L04AC
ATC
Interleukin inhibitors
+∞
8.4
8
*
J30.3
ICD-10 Finland
Other allergic rhinitis
5.4
8.1
23
44
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
8.0
51
196
D07AB01
ATC
clobetasone; topical
4.3
7.9
28
68
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
45.7
7.7
9
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.3
7.7
76
369
D07AC03
ATC
desoximetasone; topical
6.9
7.7
18
27
C01CA24
ATC
epinephrine; parenteral
3.5
7.6
34
102
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.0
7.6
43
152
E000005
ATC
NA
81.2
7.4
8
*
WQ066
NOMESCO Finland
NA
81.2
7.4
8
*
299
Kela drug reimbursment
NA
81.2
7.4
8
*
L08.0
ICD-10 Finland
Pyoderma
11.1
7.3
13
12
R06AX13
ATC
loratadine; oral
2.2
7.3
72
349
D06AX01
ATC
fusidic acid; topical (antibiotics for topical use)
2.5
7.3
57
247
J02AB02
ATC
ketoconazole; oral
4.8
7.1
22
47
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
7.2
7.0
16
23
RJ421
NOMESCO Finland
NA
14.0
6.9
11
8
A10BA02
ATC
metformin; oral
1.8
6.9
142
912
E0001A1
ATC
NA
6.8
6.9
16
24
L50.0
ICD-10 Finland
Allergic urticaria
11.1
6.8
12
11
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
4.3
6.7
23
55
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
22.9
6.7
9
*
103
Kela drug reimbursment
Diabetes, insulin-treated
1.8
6.6
138
884
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.5
6.6
52
225
NH3EA
NOMESCO Finland
Feet X-ray examination with load
4.6
6.5
21
47
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
5.0
6.4
19
39
SPAT1263
SPAT
Sampling
1.7
6.4
199
1432
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.7
6.4
189
1343
75720
ICD-8 Finland
Congenital anomalies of skin, hair and nails, Iethyosis congenita
+∞
6.3
6
*
WQ053
NOMESCO Finland
NA
+∞
6.3
6
*
Q80.2
ICD-10 Finland
Lamellar ichthyosis
+∞
6.3
6
*
XX9XT
NOMESCO Finland
Other radiological intervention
27.0
6.2
8
*
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
5.5
6.2
17
32
L50.9
ICD-10 Finland
Urticaria, unspecified
12.7
6.1
10
8
I10
ICD-10 Finland
Essential (primary) hypertension
1.6
6.1
267
2094
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
10.2
6.1
11
11
RS121
NOMESCO Finland
NA
10.2
6.1
11
11
SPAT1254
SPAT
Administration of medicine
2.1
6.0
69
355
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.0
6.0
75
400
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
62
66
10.52
53.49
3.0
3.3
4.0
4.3
e9/l
0.28
62
66
63
69
10.24
53.24
3.1
3.5
56.2
56.2
%
0.01
63
69
376
1972
4.19
50.80
13.6
6.0
27.6
27.2
%
0.35
370
1848
372
1941
4.14
50.53
13.0
5.8
56.7
57.7
%
0.99
366
1834
415
2354
4.64
49.57
14.6
9.7
4.1
4.2
e9/l
0.33
404
2072
25
13
20.14
32.00
1.9
1.2
9.0
9.0
ug/l
0.01
25
13
62
124
5.54
30.19
1.9
1.6
0.0
0.1
iu/ml
—
5
29
85
222
4.38
30.11
1.9
1.3
3380.0
214.6
u/ml
3.83
78
198
202
1060
2.47
21.15
5.2
3.7
0.0
0.0
estimate
0.50
97
345
25
29
9.00
19.92
1.5
1.3
22.9
27.5
%
0.18
11
22
106
418
2.92
19.53
4.7
3.4
—
—
—
0
0
407
3004
2.58
18.55
6.3
4.0
14.1
11.8
mm/h
2.13
380
2777
417
3129
2.62
18.06
12.0
8.0
82.9
77.9
u/l
1.42
404
2938
103
453
2.58
15.13
4.0
4.2
235.0
236.7
u/l
0.07
92
429
244
1552
2.07
14.67
5.5
3.7
—
—
—
0
0
286
1959
2.01
13.68
5.2
3.5
0.0
0.0
estimate
0.00
102
356
285
1960
1.99
13.36
6.5
4.9
0.0
0.0
estimate
0.00
106
360
286
1984
1.97
12.92
5.2
3.6
0.0
0.0
estimate
0.00
98
341
16
5
32.93
12.63
2.1
1.2
—
—
—
0
0
75
313
2.63
12.13
5.3
4.6
1.2
1.2
mmol/l
0.63
66
281
145
810
2.09
11.93
1.9
1.7
119130815.5
22431691.4
pmol/l
0.37
115
691
18
26
7.13
11.92
1.8
2.2
—
—
—
0
0
18
27
6.87
11.53
1.8
2.1
12.9
16.4
%
—
8
16
38
117
3.42
10.47
2.2
1.7
—
—
—
0
0
121
672
2.04
9.92
3.1
3.5
0.8
0.8
mmol/l
0.25
110
634
22
47
4.84
9.85
2.1
2.6
32.9
33.5
pg
0.26
22
47
71
321
2.40
9.65
1.8
3.0
66.8
66.5
g/l
0.10
59
293
20
41
5.03
9.38
1.2
1.4
—
—
—
0
0
46
171
2.85
9.26
1.9
2.1
0.9
2.0
ug/l
0.88
38
153
21
47
4.61
8.91
1.8
1.4
62.1
62.0
%
—
9
41
190
1295
1.73
7.94
4.8
3.9
15.9
8.5
mg/mmol
0.94
117
868
147
954
1.75
7.20
2.6
2.0
3.5
3.1
mg/l
0.82
117
831
236
1746
1.64
7.02
5.9
4.9
34.2
35.7
g/l
3.13
216
1639
71
369
2.07
6.85
2.9
2.0
271.6
382.6
nmol/l
6.10
65
342
223
1636
1.63
6.80
4.1
3.7
30.2
40.9
ng/l
1.41
160
1140
19
49
3.99
6.76
1.2
1.1
—
—
—
0
0
31
113
2.85
6.49
1.5
1.2
—
—
—
0
0
275
2142
1.60
6.43
6.4
6.9
11.3
11.6
umol/l
0.17
260
2045
97
576
1.84
6.33
2.9
2.3
2.4
2.3
g/l
0.52
85
536
162
1113
1.66
6.31
2.9
2.7
5539.2
7997.5
umol/l
0.26
142
972
10
8
12.71
6.10
2.0
1.9
—
—
—
0
0
184
1324
1.60
5.88
3.4
3.1
7.6
8.2
mmol/l
1.15
145
1103
24
82
3.02
5.64
2.3
2.2
16.0
16.2
%
0.06
11
43
201
1490
1.57
5.60
4.3
3.2
—
—
—
0
0
90
542
1.80
5.58
6.8
5.6
1.1
1.0
mmol/l
1.26
85
503
459
4133
1.88
5.49
21.9
14.4
20.5
24.6
mg/l
2.21
403
3292
100
628
1.73
5.36
3.0
2.3
12.7
13.2
umol/l
0.27
89
582
110
714
1.68
5.22
2.1
1.7
1246.7
1181.7
nmol/l
0.34
83
557
125
839
1.64
5.22
1.3
1.2
4.1
1.3
u/ml
0.65
43
232
90
553
1.76
5.20
3.0
2.3
22.7
23.3
%
0.14
78
479
27
104
2.68
5.14
1.3
1.7
—
—
—
0
0
14
36
3.97
5.01
1.4
1.7
—
—
—
0
0
178
1316
1.53
4.88
2.6
2.5
51.1
57.3
u/l
2.10
165
1231
67
385
1.85
4.83
2.7
2.2
0.2
0.2
g/l
0.53
60
357
18
57
3.23
4.80
1.1
1.1
1.2
1.1
u/ml
0.07
13
24
70
1106
0.58
4.46
2.9
2.9
0.6
0.8
ug/l
2.50
45
710
395
3494
1.53
4.19
27.3
17.4
14.0
13.7
%
4.31
387
3433
30
137
2.26
4.04
1.9
3.9
29.1
36.2
mg/l
0.68
18
112
30
137
2.26
4.04
1.9
3.9
63.4
106.8
mg/l
0.37
17
110
9
14
6.52
4.00
1.2
1.0
978.9
1587.7
miu/ml
—
9
14
18
65
2.83
3.89
1.4
1.6
—
—
—
0
0
199
1566
1.44
3.81
2.6
2.2
72.9
75.7
nmol/l
0.78
178
1400
28
129
2.24
3.71
6.5
3.8
4.0
4.0
mmol/l
0.02
23
119
20
80
2.56
3.59
1.4
1.9
—
—
—
0
0
291
2469
1.40
3.54
6.3
4.9
7.0
6.7
mmol/l
1.11
276
2317
8
14
5.78
3.35
3.9
5.5
—
—
—
0
0
17
66
2.63
3.24
1.2
1.3
—
—
—
0
0
27
132
2.10
3.12
1.9
2.1
—
—
—
0
0
24
112
2.20
3.11
1.3
1.7
—
—
—
0
0
178
1414
1.39
3.10
4.3
3.5
39.1
34.0
u/l
1.25
166
1345
24
113
2.18
3.05
1.3
1.8
—
—
—
0
0
14
51
2.79
3.00
1.4
1.7
—
—
—
0
0
16
63
2.59
2.98
1.2
1.7
—
—
—
0
0
116
1513
0.70
2.88
3.8
4.1
19.8
21.1
%
0.44
44
688
333
2952
1.35
2.76
4.6
3.5
14.7
14.8
pmol/l
0.34
294
2670
45
274
1.70
2.72
4.8
3.3
1.5
1.8
mmol/l
0.23
35
209
58
378
1.60
2.71
4.5
3.5
2.4
2.0
mmol/l
0.23
39
302
146
1147
1.38
2.67
3.6
3.1
0.3
0.5
e6/l
1.09
127
854
10
32
3.17
2.66
1.8
3.3
—
—
—
0
0
86
617
1.47
2.60
1.3
1.3
9.0
10.9
u/ml
0.10
42
239
11
38
2.94
2.59
1.4
1.2
—
—
—
0
0
9
25
3.64
2.58
1.2
1.6
—
—
—
0
0
9
25
3.64
2.58
1.2
1.6
—
—
—
0
0
33
187
1.82
2.55
1.8
1.7
1.6
1.5
g/l
0.14
25
163
156
1248
1.36
2.53
2.1
2.1
144.9
339.4
u/l
1.71
147
1181
7
16
4.42
2.48
2.6
2.0
—
—
—
0
0
194
1609
1.33
2.46
2.1
1.9
91.5
94.6
pmol/l
0.47
116
860
232
1975
1.31
2.44
8.4
7.0
1.2
1.2
mmol/l
2.04
163
1689
46
292
1.63
2.40
1.7
1.5
—
—
—
0
0
21
105
2.04
2.34
1.4
1.5
0.7
0.9
nmol/l
0.69
16
93
425
3959
1.39
2.26
23.7
13.1
83.5
82.0
ml/min/173m2
0.68
378
3272
9
29
3.14
2.23
1.2
1.6
—
—
—
0
0
16
73
2.23
2.23
1.2
1.6
—
—
—
0
0
11
42
2.65
2.19
1.2
1.1
44.5
53.9
u/l
—
6
26
117
914
1.36
2.19
1.7
1.7
1.3
1.2
mg/l
0.16
91
703
7
19
3.72
2.15
3.9
2.1
—
—
—
0
0
6
14
4.32
2.15
1.0
1.0
—
—
—
0
0
196
1654
1.30
2.13
3.2
2.6
147.8
149.7
ug/l
0.04
173
1527
9
31
2.94
2.08
1.1
1.3
—
—
—
0
0
146
1199
1.30
1.92
3.7
3.1
2809.3
1261.0
ng/l
0.71
122
1014
51
352
1.50
1.89
2.4
2.6
7.5
8.4
ug/l
0.14
40
315
60
816
0.70
1.84
3.4
3.9
641.3
387.4
ng/l
0.22
44
639
16
80
2.03
1.81
1.3
1.6
—
—
—
0
0
87
672
1.35
1.75
1.9
1.9
—
—
—
0
0
7
24
2.94
1.72
2.1
1.3
—
—
—
0
0
6
19
3.18
1.66
1.3
1.0
—
—
—
0
0
13
63
2.09
1.61
1.2
1.6
—
—
—
0
0
7
26
2.71
1.58
2.3
3.8
—
—
—
0
0
6
21
2.88
1.51
1.2
1.0
—
—
—
0
0
9
38
2.39
1.46
1.1
1.3
—
—
—
0
0
23
141
1.66
1.44
1.3
2.4
11.6
10.7
g/l
0.16
16
121
6
22
2.75
1.44
1.0
1.1
189.3
236.1
iu/ml
—
6
22
463
4447
1.35
1.41
22.2
10.4
29.9
28.5
u/l
0.80
457
4309
22
134
1.67
1.41
2.5
2.6
237.5
120.1
ug/min
0.37
12
78
19
111
1.74
1.41
1.6
1.6
—
—
—
0
0
19
111
1.74
1.41
1.4
1.5
241.8
261.5
ug/g
0.16
11
67
17
96
1.80
1.40
1.5
1.4
—
—
—
0
0
111
917
1.27
1.38
1.9
1.5
20.8
20.4
nmol/l
0.07
91
777
37
520
0.69
1.38
5.0
4.3
26.5
31.1
%
2.15
25
357
19
112
1.72
1.37
3.5
3.4
37.2
34.0
umol/l
0.34
13
92
5
17
2.96
1.36
1.8
3.8
232.2
204.1
u/l
—
5
17
9
42
2.16
1.34
3.6
2.1
—
—
—
0
0
106
880
1.26
1.27
5.8
3.8
1.0
1.0
kg/l
0.01
13
126
19
115
1.68
1.26
1.3
1.3
98.7
246.5
miu/ml
—
6
55
82
661
1.29
1.25
1.5
1.4
—
—
—
0
0
202
1798
1.20
1.23
7.8
6.1
1.2
1.2
mmol/l
1.88
180
1644
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
19
2.65
1.22
1.4
1.3
—
—
—
0
0
15
86
1.77
1.20
1.6
1.5
—
—
—
0
0
283
2603
1.19
1.19
6.1
4.2
1285.2
1603.6
e6/l
0.07
15
38
73
585
1.29
1.17
2.0
1.8
1.9
1.5
%
2.27
66
520
8
39
2.07
1.15
1.0
1.1
—
—
—
0
0
28
396
0.69
1.11
1.7
1.7
—
—
—
0
0
10
52
1.94
1.06
1.6
1.2
—
—
—
0
0
79
648
1.26
1.06
1.4
1.3
20.1
33.4
iu/ml
1.23
25
202
461
4461
1.27
1.03
29.0
16.7
84.6
80.2
umol/l
1.15
461
4461
23
155
1.51
1.03
1.3
2.3
—
—
—
0
0
23
155
1.51
1.03
1.3
2.3
3.9
3.9
g/l
0.00
12
111
23
155
1.51
1.03
1.3
2.3
6.8
7.5
g/l
0.57
12
117
22
147
1.52
1.02
2.2
1.8
—
—
—
0
0
5
23
2.18
0.98
1.0
3.2
—
491.8
—
0
5
0
29
0.00
0.98
0.0
1.1
—
1.1
—
0
16
0
30
0.00
0.97
0.0
1.0
—
589.3
—
0
18
0
30
0.00
0.97
0.0
1.0
—
33.7
—
0
16
22
149
1.50
0.97
3.1
2.9
—
—
—
0
0
54
673
0.78
0.96
3.4
2.9
3.0
1.7
e6/l
0.44
33
378
0
32
0.00
0.95
0.0
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
125
1.54
0.95
2.8
2.3
0.4
0.3
u/ml
0.16
11
68
416
3993
1.20
0.94
5.9
3.9
1.5
1.3
mmol/l
2.11
391
3685
386
3682
1.18
0.94
5.2
4.2
2.1
2.2
mu/l
0.21
343
3361
445
4302
1.23
0.92
21.9
16.4
4.0
4.0
mmol/l
0.05
432
4193
23
160
1.46
0.90
2.6
2.0
—
—
—
0
0
5
101
0.49
0.90
1.2
1.4
—
—
—
0
0
304
2855
1.15
0.87
4.8
3.2
75.9
52.2
u/l
2.69
283
2676
442
4287
1.20
0.77
22.1
16.3
139.2
139.6
mmol/l
3.47
428
4183
13
196
0.65
0.75
2.3
1.8
—
—
—
0
0
33
422
0.77
0.74
1.7
1.5
—
—
—
0
0
7
38
1.85
0.73
1.0
1.5
—
—
—
0
0
58
484
1.22
0.71
12.4
7.1
—
—
—
0
0
174
1894
0.88
0.70
3.8
4.6
1.6
2.4
ug/l
2.52
155
1711
13
190
0.68
0.66
1.2
1.3
—
—
—
0
0
5
28
1.79
0.66
2.8
3.2
27.6
67.5
u/ml
—
5
28
399
3856
1.14
0.65
7.5
5.7
41.6
40.1
mmol/mol
2.08
361
3601
18
129
1.41
0.64
1.2
1.6
—
—
—
0
0
5
29
1.73
0.64
1.4
1.1
—
—
—
0
0
10
153
0.65
0.63
2.5
1.8
—
—
—
0
0
18
130
1.40
0.62
1.4
2.6
1.7
1.3
g/l
0.13
12
117
143
1306
1.13
0.59
3.0
3.3
2.3
2.3
mmol/l
0.97
125
1152
17
123
1.39
0.58
1.4
2.4
40.4
37.4
g/l
—
10
105
0
23
0.00
0.58
0.0
1.5
—
—
—
0
0
426
4146
1.15
0.57
6.3
4.4
4.5
4.6
mmol/l
1.95
402
3854
56
478
1.19
0.57
1.4
1.9
—
—
—
0
0
32
392
0.80
0.54
3.5
2.5
66.0
165.8
u/l
0.38
27
337
206
1936
1.11
0.51
5.2
4.1
—
—
—
0
0
32
261
1.24
0.51
1.8
1.5
—
—
—
0
0
6
41
1.47
0.50
1.2
1.5
—
—
—
0
0
6
41
1.47
0.50
1.5
1.9
—
—
—
0
0
6
41
1.47
0.50
1.5
1.9
—
—
—
0
0
6
41
1.47
0.50
1.5
1.9
—
—
—
0
0
19
146
1.31
0.47
1.3
2.3
2.7
3.2
g/l
2.32
12
114
11
77
1.44
0.46
1.4
1.4
—
—
—
0
0
7
50
1.41
0.45
1.4
2.1
—
—
—
0
0
16
121
1.33
0.44
3.4
3.2
1.8
1.5
mg/l
0.47
16
111
8
57
1.41
0.42
1.5
2.0
—
—
—
0
0
13
96
1.36
0.42
3.7
2.3
1619.4
3499.3
u/l
—
8
37
0
16
0.00
0.41
0.0
1.8
—
61.5
—
0
16
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
268
2572
1.09
0.40
2.7
2.9
—
—
—
0
0
7
104
0.67
0.39
1.4
1.1
—
—
—
0
0
8
61
1.32
0.39
1.0
1.0
1.7
1.5
g/l
—
8
52
10
71
1.42
0.39
1.7
1.5
—
—
—
0
0
5
36
1.39
0.38
1.0
1.1
—
68.0
—
0
5
9
69
1.31
0.37
1.2
1.7
—
—
—
0
0
5
77
0.65
0.36
1.4
1.6
—
—
—
0
0
6
42
1.43
0.35
1.3
1.8
—
—
—
0
0
53
472
1.14
0.35
1.4
1.9
—
—
—
0
0
55
492
1.13
0.34
4.6
3.1
7.6
8.7
umol/l
0.30
44
446
65
711
0.90
0.30
3.0
2.7
1.2
1.1
e6/l
0.06
44
414
26
222
1.18
0.30
1.1
1.2
43.6
152.3
iu/ml
—
8
90
419
4126
1.08
0.26
5.3
4.3
1.3
1.4
mmol/l
2.67
385
3819
10
127
0.78
0.25
1.2
2.2
11.1
12.3
mg/l
—
10
117
15
123
1.23
0.25
1.1
1.2
—
—
—
0
0
9
76
1.19
0.24
1.6
1.2
—
32.5
—
0
10
35
391
0.89
0.24
2.2
1.9
—
—
—
0
0
11
88
1.26
0.22
1.2
1.2
—
—
—
0
0
5
43
1.16
0.21
1.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.4
—
0
8
6
49
1.23
0.20
1.3
1.7
—
—
—
0
0
12
144
0.83
0.20
1.2
1.6
—
—
—
0
0
6
50
1.20
0.19
1.0
1.1
—
—
—
0
0
6
52
1.16
0.19
1.0
1.1
—
—
—
0
0
10
81
1.24
0.19
1.0
1.2
14.4
56.5
u/l
—
10
70
11
132
0.83
0.18
1.1
1.2
—
—
—
0
0
426
4215
1.06
0.17
5.7
4.8
2.7
2.7
mmol/l
1.27
392
3895
15
172
0.87
0.16
1.0
1.0
—
—
—
0
0
6
79
0.76
0.15
1.2
1.3
—
—
—
0
0
6
79
0.76
0.15
1.2
1.3
—
—
—
0
0
30
274
1.10
0.15
4.6
3.9
79.3
84.1
ng/l
0.16
23
243
40
428
0.93
0.14
2.0
2.0
—
—
—
0
0
101
974
1.05
0.13
3.5
2.4
—
—
—
0
0
5
45
1.11
0.10
4.2
2.9
3.9
3.4
nmol/l
—
5
45
19
207
0.91
0.09
2.1
3.7
3.7
4.6
pmol/l
2.39
12
185
6
54
1.11
0.09
1.3
1.5
—
—
—
0
0
6
55
1.09
0.09
1.3
1.5
—
—
—
0
0
6
55
1.09
0.09
1.3
1.5
—
—
—
0
0
6
55
1.09
0.09
1.3
1.5
—
—
—
0
0
6
56
1.07
0.08
1.3
1.5
—
—
—
0
0
52
499
1.05
0.08
10.0
7.6
1.4
1.0
mmol/l
0.27
39
402
34
322
1.06
0.08
3.2
2.8
58.5
67.0
ml/min/173m2
0.79
15
131
10
113
0.88
0.08
1.1
1.1
—
—
—
0
0
10
112
0.89
0.07
1.1
1.1
—
—
—
0
0
8
93
0.86
0.06
1.3
1.3
—
—
—
0
0
11
99
1.11
0.06
1.5
1.3
—
2.2
—
0
6
406
4039
1.02
0.06
5.2
4.4
6.2
6.0
mmol/l
1.32
365
3702
52
536
0.97
0.05
24.4
23.8
1.1
1.3
inr
—
10
66
25
239
1.05
0.04
1.5
1.7
—
—
—
0
0
382
3835
0.99
0.03
21.6
14.8
39.9
40.5
%
0.54
227
2815
110
1113
0.99
0.03
2.0
1.6
1.6
1.5
mmol/l
0.40
81
946
13
125
1.04
0.00
1.5
1.8
83.5
88.6
%
0.27
13
115
43
425
1.01
0.00
3.5
4.7
10.2
40.1
ug/l
0.84
33
353
10
101
0.99
0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
1.2
—
0
9
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
27.4
—
0
9
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
7
75
0.93
0.00
1.3
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
5
55
0.91
0.00
1.4
1.5
—
—
—
0
0
7
77
0.91
0.00
1.4
1.2
—
—
—
0
0
7
74
0.95
0.00
1.3
1.4
—
—
—
0
0
6
60
1.00
0.00
1.2
1.0
—
—
—
0
0
7
79
0.88
0.00
1.3
1.6
—
—
—
0
0
7
75
0.93
0.00
1.3
1.4
—
—
—
0
0
7
72
0.97
0.00
1.3
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ERYTHRO_KELA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.756 [1.38, 2.24] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.201 |
During the follow-up period (1.1.1998 — 31.12.2019), 107 out of 680 females with L12_ERYTHRO_KELA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.919 [1.61, 2.28] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 254 out of 1333 males with L12_ERYTHRO_KELA died.
Mortality risk
Mortality risk for people of age
years, who have L12_ERYTHRO_KELA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.426% |
| 5 | 0.981% | 2.332% |
| 10 | 2.483% | 6.368% |
| 15 | 4.943% | 11.795% |
| 20 | 8.337% | 19.381% |
Relationships between endpoints
↥Index endpoint: L12_ERYTHRO_KELA – Universal erythroderma, KELA reimbursement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data